H.E.L Group strengthens leadership team to focus on new product development and enhanced customer support
Alan Lockley joins as Director of Global Services, Edward Quinn as Director of Product Development and Mark Appleton takes new role as Director of Research.
PhoreMost enters multi-project drug target discovery collaboration with Roche
PhoreMost to deploy its SITESEEKER platform to identify novel targets for Roche’s discovery programmes.
Avacta announces AVA6000 receives Orphan Drug Designation from the US Food and Drug Administration
London and Wetherby, UK - Avacta Group plc, a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the company’s lead pre|CISION drug candidate, AVA6000, for treatment of soft tissue sarcoma.
Guardtech going for gold at four awards evenings in space of four months
The cleanroom construction Group are up for five honours at glitzy showpieces in London and Cambridgeshire.
Global Access Diagnostics acquires manufacturing rights for IT-LEISH rapid diagnostic test from Bio-Rad Laboratories
Bedford, UK - Global Access Diagnostics (GADx), a social enterprise prioritising equitable access to diagnostics and driving local manufacturing, announces it has acquired the manufacturing rights for the IT-LEISH rapid diagnostic test (RDT) for visceral leishmaniasis (VL) from Bio-Rad, a global leader in life science research and clinical diagnostic products.
Why isn’t Adaptability more of a priority?
Well, when I put that question to the talented members of the Scottish Institute for Business Leaders this week, their wide-ranging and insightful answers included a clutch of stand-out insights:
What are best practices from other MedTech startups? The case of Bilihome
Partnering with F.INSTITUTE, Bilihome successfully attracted investors and created realistic financial scenarios for its development, certification, and product launch phases. F.INSTITUTE supports Bilihome’s financial services, including accounting, financial modeling, and the role of CFO, payroll administration, and partially subsidy advisor.
Oxford Innovation Space appoints Gary Jennings as new Innovation Director at The Epicentre, Haverhill
Oxford Innovation Space has appointed Gary Jennings as the new Innovation Director at The EpiCentre in Haverhill alongside Centre Manager, Andrew Bell.
Avacta announces Phase I clinical study of AVA6000 to advance to the fourth cohort
London and Wetherby, UK - Avacta Group plc, a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces that the first-in-human Phase I trial (ALS-6000-101) of AVA6000 Pro-doxorubicin will advance to the fourth dose cohort of patients following a positive review of the safety and tolerability data from the…
High-flying Guardtech prepare for string of international exhibitions
The cleanroom construction kings and queens are set for shows in Ireland, Germany and Singapore.
Hardware verification: are you meeting all your requirements?
Hardware verification provides evidence that a production representative sample of your medical device meets the issued hardware requirements. Unlike during software verification, which requires verification activities throughout the development, formal hardware verification is performed entirely at the end of the design process, although much of the preparation must occur earlier in the project.
Government is running out of time to support businesses in urgent need
The British Chambers of Commerce (BCC) has written to the Prime Minister, Chancellor of the Exchequer and both leadership candidates for the Conservative Party proposing a comprehensive five-point plan to provide vital support to UK businesses.
Bio-Rad introduces anti-evolocumab antibodies for use in preclinical and clinical drug development
HERCULES, Calif. — Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, introduces a range of type 1 antibodies that inhibit the binding of evolocumab (Repatha®) to its target, human proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that has been shown to play a key role in the regulation of cholesterol levels. These sequence…
Can medical devices be discriminatory?
The UK government has recently called for evidence of discrimination in medical devices. The aim is to identify how devices and technologies may be biased against different genders, ethnicities and other socio-demographic groups. This begs the question – can medical devices be designed to discriminate against certain users? The short answer is yes – but not intentionally. While it is, of…
Solving your drug delivery needs at PDA
Brennan Miles, John Burke, Chris Hurlstone and Alastair Willoughby from Team Consulting will be attending the 2022 PDA Universe of Pre-Filled Syringes and Injection Devices Conference, live in Palm Springs from 18th-19th October.
Can you do too much system engineering?
These days, a medical device needs to be considered as one element of a connected whole. Systems engineering has become a crucial part of medical device development, but can you do too much of it? Our Head of Electronics Engineering, Peter Matthewson, discusses in a new blog post.
Delivering the most viscous drug ever put in an autoinjector
Autoinjectors offer patients a smart way to get their medication. Some drugs however can be too viscous for this type of delivery. Find out how Springboard helped a client solve the tricky problem of administering a highly viscous drug via and autoinjector, helping patients around the world to access their medication.
Computational chemistry news 2022
Computational chemistry news from Cresset, including: custom force fields, molecular dynamics, molecular scaffolds, clustering algorithms in Spark, Cresset Discovery, small molecule design.
Evonetix commences early access program for DNA synthesised by thermal control on its semiconductor chip
Cambridge, UK - Evonetix, the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the opening of its early access program for semiconductor synthesised DNA. Evonetix’s DNA synthesis capability brings together patented semiconductor chip design and proprietary, thermally controlled synthesis chemistry, which will be integral to the Company’s future gene…
Keep your facility up to standard with Guardtech’s Decontamination Team
Cleanroom construction specialists Guardtech Group helping clients shine with their high-performance deep clean programmes
Sketch club - Sketch & Social launches in Cambridge
A bi-weekly meet-up for creatives in and around Cambridge, coming together over sketching in a fun and informal group.
IQGeo announces acquisition of Comsof NV
Cambridge - IQGeo, a developer of geospatial software that is “Building better networks” for telecom and utility operators, is pleased to announce the acquisition of Comsof NV (Comsof) and its industry-leading fiber optic network automated planning and design software. The IQGeo Group has agreed to acquire Comsof for a total consideration of up to €13m through a combination of cash, and shares.
Bio-Rad extends range of StarBright Violet and UltraViolet Dyes for multiplex flow cytometry
HERCULES, Calif, — Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, extends its range of StarBright Dyes to provide greater flexibility in multicolor flow cytometry panels. The StarBright Violet 760, StarBright UltraViolet 575, and StarBright UltraViolet 605 Dyes offer improved brightness with narrow excitation and emission profiles for…
Inspira Pharmaceuticals joins the Lab Hotel at Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst (SBC) welcomes Inspira Pharmaceuticals to its Lab Hotel, a unique facility offering free lab and office accommodation for six months. The start-ups receive scientific and business support, access to SBC’s networks and introductions to investors to help their business grow and develop.
Arecor granted european patents protecting proprietary formulations of high concentration Humira® Biosimilar
Cambridge, UK - Arecor Therapeutics plc, the biopharmaceutical group advancing today’s therapies to enable healthier lives, is pleased to announce that the European Patent Office has granted two patents (EP3592383B1 and EP3592385B1) protecting the Group’s novel formulations of high-concentration adalimumab until 2038.